For instance, treating BRCA1/2-mutated tumors with PARP inhibitors is a classic example of taking advantage of a cancer-specific mutation to selectively kill cancer cells by depriving them of a biological mechanism (DNA damage repair) that compensates for this genetic deficiency (Figure 6) [152,153,154]. Here, BRCA1 is linked to cancer.